Lenvatinib Combined Toripalimab in Advanced Hepatocellular Carcinoma
Status:
Recruiting
Trial end date:
2023-04-01
Target enrollment:
Participant gender:
Summary
The investigators design a phase IIB clinical study to explore the efficacy and safety of
Lenvatinib plus Toripalimab in patients with advanced hepatocellular carcinoma and to analyze
potential biomarkers of therapeutic response.